PCM
APLT

Peregrine Capital Management’s Applied Therapeutics APLT Stock Holding History

Peregrine Capital Management’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-664,740
Closed -$5.65M – 334
2024
Q3 		$5.65M Sell
664,740
-66,308
-9% -$391K 0.17% 195
2024
Q2 		$3.41M Buy
+731,048
New +$3.46M 0.1% 245

Other funds holding APLT

VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Peregrine Capital Management's APLT Position: Q4 2024 in Review

Peregrine Capital Management sold out of Applied Therapeutics (APLT) in Q4 2024, closing a stake of 664,740 shares — an estimated $5.65M sold.

Peregrine Capital Management first reported a position in APLT in Q2 2024 and held it in 2 quarters. The position peaked at $5.65M in Q3 2024. 119 funds tracked by Wall St. Rank hold APLT as of Q4 2024.

  • Peregrine Capital Management reported no remaining Applied Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Peregrine Capital Management sold 664,740 Applied Therapeutics shares in Q4 2024, an estimated $5.65M.
  • Peregrine Capital Management first reported a position in Applied Therapeutics in Q2 2024 and held it in 2 quarters.
  • Peregrine Capital Management's Applied Therapeutics position peaked at $5.65M in Q3 2024.
  • 119 funds tracked by Wall St. Rank held Applied Therapeutics as of Q4 2024.

Based on Peregrine Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.